Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Faldaprevir + PegIFN/RBV in HCV Genotype 1
NCT00774397Phase 2Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Oct 2008
- Primary completion
- Nov 2011
- Modality
- Small Molecules, Modified Peptides
- Countries
- 15
01
Overview
A Phase 2 trial of faldaprevir in hepatitis C (HCV), sponsored by Boehringer Ingelheim. Started Oct 2008; status: completed.
02
Drugs
faldaprevir
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT00774397.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00774397.